anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Calculated CVP value as VCI (vena cava inferior) index by Marcelino P et al. method-they reported that VCI index using several echocardiographic parameters measured. A transthoracic echocardiographic study was performed using an Aloka SSD 2200 echocardiograph fitted with 2.5MHz probe with continuous-wave，pulsed and color Doppler (Japan). Using pulsed Doppler，each parameter is measured as following; the deceleration rime of E wave of tricuspid inflow，the gradient between right ventricle (RV) and right atrium (RA) by continuous Doppler，the VCI variation from the corresponding maximum expiratory diameter (measured at 2 cm from the RA and in dorsal decubitus) to its diameter during inspiration. All measurements were taken at the end-expiration in order to standardize the samples. VCI index = \[tricuspid E deceleration (ms)\] x 0.11 + \[RV/RA gradient (mmHg)\] x 0.16 - \[VCI variation (mm)\] (VCI, vena cava inferior; tricuspid E, tricuspid E wave; RV, right ventricle, RA, right atrium).

Na, Cl, K, creatinine, BUN and uric acid in serum and urine were measured by the usual methods before and after the correction of plasma volume. Further, osmolality and vasopressin in plasma and osmolality in urine were also measured by the usual methods.
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is an inflammatory multisystemic disease caused by environmental exposures and/or genetic factors. Inherited alpha-1-antitrypsin deficiency (AATD) is one of the best recognized genetic factors increasing the risk for an early onset COPD with emphysema. The aim of this study was to gain a better understanding of the associations between comorbidities and specific biomarkers in COPD patients with and without AATD to enable future investigations aimed, for example, at identifying risk factors or improving care.
METHODS: We focused on cardiovascular comorbidities, blood high sensitivity troponin (hs-troponin) and lipid profiles in COPD patients with and without AATD. We used clinical data from six German University Medical Centres of the MIRACUM (Medical Informatics Initiative in Research and Medicine) consortium. The codes for the international classification of diseases (ICD) were used for COPD as a main diagnosis and for comorbidities and blood laboratory data were obtained. Data analyses were based on the DataSHIELD framework.
RESULTS: Out of 112,852 visits complete information was available for 43,057 COPD patients. According to our findings, 746 patients with AATD (1.73%) showed significantly lower total blood cholesterol levels and less cardiovascular comorbidities than non-AATD COPD patients. Moreover, after adjusting for the confounder factors, such as age, gender, and nicotine abuse, we confirmed that hs-troponin is a suitable predictor of overall mortality in COPD patients. The comorbidities associated with AATD in the current study differ from other studies, which may reflect geographic and population-based differences as well as the heterogeneous characteristics of AATD.
CONCLUSION: The concept of MIRACUM is suitable for the analysis of a large healthcare database. This study provided evidence that COPD patients with AATD have a lower cardiovascular risk and revealed that hs-troponin is a predictor for hospital mortality in individuals with COPD.
This study will enroll up to 24 participants and will include 2 hepatic impaired participant groups and one group of control participants with normal hepatic function. Approximately four participants with mild hepatic impairment will be enrolled first (Group 1). To ensure participant safety, following dosing of these first four participants, a safety meeting will take place to review the safety data prior to dosing additional participants. After safety and pharmacokinetic (PK) results from the first four participants have been reviewed, an additional four participants with mild hepatic impairment (remainder of Group 1) will be enrolled concurrently with the moderate hepatic impairment group (Group 2). Thereafter, matched participants with normal hepatic function (Group 3) will be enrolled. All participants will participate in one treatment period and will receive a single dose of lasmiditan in the fasting state.
Particiants in this group will receive a single injection for femoral nerve block intra-operatively combined continuous femoral nerve block post-operatively. This technique will be guided by ultrasound and nerve stimulator.The regimen is a loading dose of 0.8% ropivacaine 30 ml intra-operatively and 0.15% ropivacaine 300ml in the form of continuous femoral nerve block post-operatively.
Participants with HBV currently not being treated will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
Participants in the long-term treatment will receive 24 weeks of active cognitive remediation. Participants will complete 24 weeks of on-line computer exercises and participate in an on-line forum to facilitate strategy monitoring and bridging strategies.
After verification of being in the intrathecal space with free-flow of cerebral spinal fluid, 1 mL of 0.25% bupivicaine along with 20 mcg of fentanyl will be injected into the intrathecal space. Subsequently, a B/Braun Perifix FX closed tip multiorifice flexible epidural catheter will be threaded 4 cm into the epidural space. After obtaining a T6 dermatomal level of sensory blockade, a standard solution consisting of 0.125% bupivicaine with 2 mcg of fentanyl/mL of solution will be started at 10 mL/hour with a patient controlled epidural analgesia (PCEA) option of 8 mL every 45 minutes. If a patient requires redosing, 5-10 mL of 0.25% bupivicaine will be injected slowly through epidural catheter with a goal dermatome level of T6. No systemic opioids will be given.
The present invention relates to a composition for skin regeneration or cell therapeutics comprising an extract of Asparagus lucidus Lindl. as an active ingredient. The extract of Asparagus lucidus Lindl. of the present invention, which is a natural plant-derived extract, has low toxicity to keratinocytes, and is effective in promoting cell growth by regulating gene expression of keratinocytes through the activation of ERK1/2. Thus, the extract of Asparagus lucidus Lindl. can be effectively used as a cosmetic composition for skin regeneration or a composition for external skin application for wound treatment.
NEW MATERIAL:A piperazine derivative of formula I (R is H, alkyl, alkoxy, halogen; n is 2, 3; m is 1-3) and its acid adduct. EXAMPLE:1-[ 2-( 3,4,5-Trimethoxycinnamoyloxy )ethyl ]-4-(2,3,4-trimethoxyphenylmethyl)piperazine. USE:It is used as a medicine for the circulation system, because it has actions on the circulation system such as peripheral vasodilation. PREPARATION:The reaction of a compound of formula II or its reactive derivative with a piperazine derivative of formula III gives a compound of formula I. An acid halide is used as a reactive derivative of the compound of formula II. When a reactive derivative is used, it is preferred to effect the reaction in the presence of an acid acceptor. In case of the reaction between cinnamic acid of formula II and a compound of formula III, the use of a condensing agent is preferred.
The procedures will be performed using standard technique with a multiband ligation device. Elastic bands will be placed according to physician decision, starting at esophagogastric junction. All varices will be treated during the same session. Endoscopic band ligation sessions will be repeated at intervals of 3 to 4 weeks until all varices will be obliterated.
The participants will perform moderate intensity exercise at heart rate corresponding with 50%WMAX (determined during maximal workload test) under mild normobaric hypoxia (FiO2: 15%), two times 30 minutes per day for 4 consecutive days on a cycle ergometer. 24h glucose concentration will be monitored continuously. Afterwards, a meal test challenge will be performed at day 5 to determine fasting/postprandial substrate oxidation.
Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12 and Week 19, all patients, regardless of their disease status, will receive ipilimumab at a dose of 1.0 mg/kg administered by IV infusion.
Temporary phases of coronary occlusion lead to an ischaemic preconditioning of the heart. This causes the affected myocardium to become more resistant with regard to longer phases of ischaemia. During ischaemic preconditioning, a series of genes are induced or preferably expressed. The invention relates to DNA sequences which code for proteins that are capable of participating during ischaemic preconditioning, especially during ischaemic preconditioning of the heart. The invention also relates to the proteins themselves, among other things, also for use as medicaments, for example for producing a composition for preventing myocardial infarctions or local contractile dysfunctions. In addition, the invention provides nucleic acid probes with which the expression of genes that play a roll during ischaemic preconditioning can be detected.
The invention provides a Jianqu and a preparation method of the Jianqu. Aims to solve the technical problem of slow fermentation speed in the prior art for preparing the Jian qu. The adopted technical scheme is as follows: the preparation method of the Jianqu comprises the following steps: crushing and uniformly mixing the raw materials to prepare a fermentation substrate, and sterilizing the fermentation substrate; uniformly mixing the composite microbial inoculum and the sterilized fermentation substrate, and preparing the mixture into blocks for fermentation; and after fermenting for 35-45 hours, taking out a fermentation product and drying to obtain the Jian Qu. Wherein the raw materials comprise: polygonum hydropiper, Xanthium sibiricum, sweet wormwood, bitter apricot seed, red bean, malt and the like. Wherein, the complex microbial inoculum comprises: powdery Mueller's yeast, Rhizomucor miehei, transverse pedunculus mycorrhiza, Monascus purpureus, Saccharomycopsis fibuligera, and Pichia bartoniensis. In addition, the invention also provides the Jian Qu prepared by the preparation method.
SITA addresses two behavioral biases observed in people living with HIV/AIDS (PLWHA). The growing field of behavioral economics (BE) suggests that people display behavioral biases (i.e. systematic decision making errors) that among patients can contribute to suboptimal adherence. Investigators observed two important such biases in our own work in Uganda: first, investigators found that patients to a large degree overestimate their own adherence, i.e. think that they adhere better than they actually do. Second, a patient's social environment matters: PLWHA clearly care about their peers and their peers' attitudes and behavior.

SITA is based on Social Cognitive Theory (SCT) and adapts two traditional interventions to mHealth. The first intervention is that of self-monitoring, i.e. providing participants with feedback about their adherence performance. Traditionally this involves clinic visits that take up provider and patient time and resources; SITA instead suggests providing objective, real-time information measured by electronic monitoring (Wisepill) devices sent to patients by weekly SMS. Such feedback builds self-efficacy, a key SCT concept and thereby may improve adherence. The second intervention is based on the SCT concept of social learning. Perceived group norms, and interventions that affect those perceptions, are a key influence on health behavior among youths, providing a substitute for direct learning. Investigators adapt this approach to a mHealth environment by providing PLWHA not only with their own adherence information but also that of a reference (peer) group.

SITA will use mixed methods research techniques and focus on knowledge transfer within a multidisciplinary team. In formative Phase 1 investigators will conduct qualitative focus groups with key stakeholders to elicit information about the use of wisepill devices, and acceptance, feasibility and locally appropriate adaptation of SITA. In Phase 2, investigators will implement a nine-months, three-arm (with 50-60 participants each) randomized controlled trial: youths in intervention group 1 will receive information about their wisepill-measured adherence level by weekly SMS. Intervention group 2 will in addition be sent the adherence level of a reference group that investigators hypothesize to exert normative influence. The control group will receive the usual standard of care. Throughout the study investigators will focus on capacity building and knowledge transfer to the Ugandan collaborators through workshops and mentoring.
PURPOSE:To obtain the titled pharmaceutical, by adding lecithin or polyglycerin fatty acid ester to a system which can be emulsified and dispersed with a sucrose fatty acid ester. CONSTITUTION:A polyglycerin fatty acid ester is added to a sucrose fatty acid ester (a hydrophilic emulsifying and dispersing agent for the preparation of an O/W-type emulsion and having an HLB value of >=6, preferably >=12 is dissolved or dispersed in water in an amount of 0.1-10w/w%, preferably 0.2-5w/w%) emulsifiable and dispersible easily in an acidic solution. The mixture is mixed with oil or fat or lecithin-containing oil or fat, and emulsified and dispersed with an emulsifying and dispersing apparatus such as homomixer to obtain an O/W- type emulsion which is useful as the objective colored pharmaceutical dispersible easily in acidic solution. The ratio of lecithin and/or polyglycerin fatty acid ester to sucrose fatty acid ester is 1/10-20 to 1. EFFECT:The problems such as clouding and precipitation, etc. can be solved.
All the patients underwent the surgical removal of cataract by the same surgeon according to the standard protocols for modern phacoemulsification. Surgery was done under local anesthesia by peri-bulbar injection of local anesthetic. All operations were performed in an operating room by using an operating microscope under complete aseptic condition by using 10% povidone iodine solution applied to the skin of eye lid, eye lashes, side of the nose, eye brow and the skin of forehead. Before the operation, sterile drape and eyelid speculum were used, then 5% povidone iodine solution was applied to the bulbar conjunctiva and fornices for about 5 minutes, then was irrigated by balanced salt solution (BSS).

All the patients were followed up at the 1st day, 1st week, 1st month and at the 3rd month after the operation. At each visit the followings should be assessed: the post-operative refraction, the best corrected visual acuity and anterior and posterior segments examination for any sign of postoperative inflammation as cells and flare. Intra-ocular pressure (IOP) assessment and optical coherence tomography (OCT) images were also taken at the 1st and the 3rd postoperative months to assess the central macular thickness in suspected cases of cystoid macular edema (CME) based upon symptoms or signs observed on fundus examination, were confirmed by OCT of the macula through subjective interpretation via presence of cysts or an objective measurement of retinal thickness \> 250 microns.
The invention discloses a polygonatum polysaccharide for preventing and/or treating autoimmune diseases. The polygonatum polysaccharide is obtained by separating and purifying rhizome of polygonatum kingianum, and the molecular weight, monosaccharide composition, chemical structure and the like of the polygonatum polysaccharide are analyzed and identified, so that the molecular weight and the structural composition of the polygonatum polysaccharide are determined. The polysaccharide mainly comprises glucose, mannose, galactose and glucuronic acid, and the molar ratio is 5. The polysaccharide is detected to be alkaline polysaccharide. After in vitro DPPH experiment and MH7A cell activity evaluation, the polysaccharide is determined to have significant anti-inflammatory immune activity. The polysaccharide can be used for preparing medicines, health products and foods for preventing and/or treating autoimmune diseases, has good application prospect and commercial value, and can also improve the utilization value of rhizoma Polygonati.
This is a longitudinal observational study. It is a 24-month study with the possibility of extending the data time points. Visits will occur monthly. However, at the discretion of the PI, subjects may not be required to return monthly. These subjects may return at intervals ranging from 2 months to a max of 6 months apart.

In the situation that the subjects would fall out of the inclusion criteria or not be eligible for the LGMD2E gene therapy trial, they will be given the opportunity to roll over into the Natural History for LGMD (IRB17-01086). If a subject is invited to screen for the gene therapy trial they will discontinue this trial. By being in this study, it is not a guarantee that subjects will be invited to screen for the LGMD2E gene therapy trial.
An oestrogen preparation comprises a rigid solid solution of an oestrogen in a water-soluble or water-miscible substance which is rigid solid at 20 DEG  C. and is capable of precipitating the oestrogen in a finely divided form on contact with an aqueous medium. Examples of the latter are polyethylene glycols (4000 or 6000), polyoxyethylene esters or ethers, polyoxyethylene sorbitan esters, and mixtures thereof.  One part of oestrogen is used for every 5 to 50 parts of the water-soluble solid.  The term "oestrogen" covers natural and synthetic oestrogens and substances having an oestrogen-like action, e.g. oestradiol, stilboestrol, oestrone, oestriol, dienoestrol, ethinyloestradiol, hexoestral, chlorotrianisene or methallenoestril, or an ester thereof, or a mixture of these substances.  The solid solution is obtained by rapidly cooling a molten solution of the oestrogen in the water-soluble or water-miscible substance, e.g. by pouring into a pan which is at room temperature.  The preparation may be powdered and compressed into pessaries along with suitable adjuvants.  The pessary may be made effervescent by incorporating therein an alkaline carbonate or bicarbonate and an organic acid such as citric and tartaric acid antibiotics such as framycetin, polymyxin or streptomycin may be incorporated in the pessaries.
BACKGROUND/OBJECTIVES: Relationship between dietary intake and sensory sensitivity and intelligence in autism spectrum disorder (ASD) is not well described. This study aims to investigate nutrition status in children with ASD and ID and its association with sensory sensitivity and intelligence.
SUBJECTS/METHODS: 84 students (34 ASD and 48 ID) in a special education school were recruited. Dietary intakes were evaluated with 3-day food dairy. Sensory sensitivity was measured using short sensory profile (SSP). Wechsler IQ test were performed.
RESULTS: Two out of twenty-four investigated nutrients had an adequate intake rate of over 50%. Four out of ten investigated vitamins had an inadequate intake rate of over 90% and another two over 80%. 75.6% of participants had inadequate energy intake. After adjusting for age, ASD participants had a higher intake of all surveyed nutrients but only the intake of vitamin E and folate were statistically different (p < 0.05) along with a smaller number of inadequate nutrients (p < 0.001). Taste/smell sensitivity, movement sensitivity, underresponsive/seeks sensation, and total sensory sensitivity symptoms severity were slightly higher in ASD group than in ID group (all p < 0.05). After adjusting for IQ and sensory sensitivity score, difference of number of inadequate nutrients between ASD and ID group were not statistically significant (p = 0.193).
CONCLUSIONS: Individuals with ASD had better dietary intake but worse sensory sensitivity compared to those with ID. Sensory sensitivity and intelligence are correlated with nutritional status in individuals with neurodevelopmental disorder.
Currently, the effectiveness of a program consisting of education to improve disease self-management combined with intensive exercises is not clear. In the present study the investigators developed a group-based program for people with RA consisting of physical exercise to increase physical performance (i.e. aerobic capacity and muscle strength) combined with an educational program to improve disease self-management (self-reported health status and self-efficacy). The investigators called it the 'FIT program'. The aim of the present randomized controlled trial (RCT) was to examine the effects of the FIT program on aerobic capacity, muscle strength, self-reported health status and self-efficacy, in a population of people with RA. The investigators hypothesized that the FIT-program would have beneficial effects on physical performance (ie. aerobic capacity and muscle strength) and disease self-management (i.e. perceived health status and self-efficacy components) compared to a waiting list control group (WLCgroup).
The treatment group was given esmolol 0.5mg/kg load, 10μg /kg/min continuous pump; Patient-controlled analgesia pump (sufentanil 2 μg/kg, 2 mL/h, for 48h) was used as the postoperative analgesia regimen in the two groups. If the VAS score was \>3, analgesic adjuvant drugs were given intravenously and recorded. If repeated treatment is ineffective, the study will be excluded.
Patients receive abexinostat PO BID on days 1-4, 8-11, and 15-18, palbociclib PO QD on days 1-21, and fulvestrant IM on days 1 and 15 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Participants will receive sham acupuncture plus usual care. The Streitberger placebo needle will be placed at non-acupuncture points which are distant from the meridian parts and not located on the same neuromuscular segments as the prescribed points used in the VA group, so as to minimize any therapeutic and segmental effects. The same acupuncture schedule as that in the verum acupuncture group will be applied. The needles are retained for 30 min in each session. During the treatment, the acupuncturist inquires the patient about deqi sensations and pretends to manipulate the needles but deqi is not sought.Participants will receive the same usual care as those in the usual care group.